A sterically stabilized immunolipoplex (TsPLP), containing an antitransferrin receptor single-chain antibody fragment (TfRscFv)-PEG molecule, has been developed to specifically and efficiently deliver a therapeutic gene to tumor cells. A postcoating preparation strategy was employed in which a DNA/lipid complex (lipoplex) was formed first and then sequentially conjugated with PEG and TfRscFv. The complex prepared by this method was shown to be superior in ability to deliver genes to tumor cells than when prepared by a common precoating strategy, in which DNA is mixed with TfRscFv-PEG conjugated liposome. Using prostate cancer cell line DU145, a comparison was made between the in vitro and in vivo gene delivery efficiencies of four complexes, Lipoplex (LP), PEG-Lipoplex (PLP), TfRscFv-PEG-Lipoplex (TsPLP) and our standard TfRscFv-Lipoplex (TsLP). In vitro, the order of transfection efficiency was TsLP4LPETsPLP4PLP. However, in vivo the order of transfection efficiency, after systemic administration via the tail vein, was TsPLP4TsLP4LP or PLP with TsPLPmediated exogenous gene expression in tumor being twofold higher than when mediated by TsLP. This suggests that the in vitro transfection efficiency of TsPLP was not indicative of its in vivo efficiency. In addition, it was found that the level of exogenous gene expression in the tumor mediated by TsPLP was higher than that mediated by TsLP and did not decrease over the time. More importantly, high exogenous gene expression in tumor, but low expression in liver, was observed after an i.v. delivery of TsPLP carrying either the GFP reporter gene or the p53 gene, indicating that tumor preferential targeting was maintained by this complex in the presence of PEG. These findings show that incorporation of PEG into our targeted lipoplex results in a more efficient delivery of the complex to the tumor cells, possibly by inhibiting the first pass clearance observed with non-PEG containing liposomes. Therefore, these data demonstrate that TsPLP is a improvement over our previously established tumor targeted gene delivery complex for systemic gene therapy of cancer.
Introduction
As cancer is often a systemic disease, the most effective gene therapy treatment would be systemically delivered. To date, many gene delivery vehicles have not been amenable to systemic administration due to their lack of targeting ability and rapid degradation within the bloodstream. 1 The ideal systemic gene delivery vehicle should be small, highly serum-stable and not readily recognized by fixed and free macrophages of the reticuloendothelial system (RES). A hydrophilic polymer, PEG (poly (ethylene glycol)), has been showed to create a steric shield around the surface of a liposome or protein, thereby conferring protection from nonspecific opsonization by plasma proteins, and resulting in enhancement of the circulation time of liposome or protein in the blood. 2 The application of this modification (PEGylation) to nonviral gene delivery systems has drawn considerable interest. [3] [4] [5] [6] [7] [8] [9] Benefits of PEGylation have been described and include improvement of systemic circulation of lipoplexes or polyplexes; 1, 10 improvement of the solubility of polyplexes thereby allowing the preparation of higher therapeutic concentrations without subsequent aggregation; 10, 11 and reduction of in vivo toxicity of the polyplex. 10 However, disadvantages of PEGylation have also been observed. These include preventing association of the polyplex with the target cells, 12 and inhibition of the release of DNA from the endosomal compartments, resulting in low transfection efficiency. 13, 14 Liposome-based gene delivery systems (lipoplexes) have been widely studied as an alternative to virusbased gene therapy vehicles. However, the in vivo gene transfer capabilities of lipoplexes have been found to be generally less effective than that of viral systems. 15 The effectiveness of a liposome-based gene delivery system can be improved by incorporating a tumor targeting ligand on the surface of these complexes, thereby enabling the lipoplex to selectively deliver its payload to tumor cells. Cellular targets for such a ligand include the transferrin receptor (TfR) or folate receptor, both of which are expressed in higher amounts on the surface of many cancer cells. Modification of the surface of a lipoplex by incorporation of folate, transferrin (Tf), or an antitransferrin receptor single-chain antibody fragment (TfRscFv) results in homing of the complex to cancer cells. In previous studies, we have shown that incorporation of Tf, TfRscFv or folate into a lipoplex greatly enhanced its ability to deliver DNA preferentially to tumor cells, and promoted specific targeting of the lipoplex to human xenograft tumors and improved antitumor efficacy after systemic administration. [16] [17] [18] [19] [20] [21] [22] However, rapid clearance from the bloodstream was also observed. This obstacle must be overcome if this systemic delivery system is to be successfully translated to the clinic. In this study, we took advantage of the serum stabilization property of PEGylation, while circumventing the problem of loss of targeting. We conjugated TfRscFv to the distal end of the steric polymer PEG and conjugated this with the preformed lipoplex to form a novel sterically stabilized gene delivery vehicle, TfRscFv-PEG-lipoplex (TsPLP). This strategy results in the targeting ligand, TfRscFv, not being blocked by the PEG 'forest', but flexibly extending away from the lipoplex, allowing the ligand to freely bind the TfR exposed extracellularly on the plasma membrane of the cancer cells.
In this study, the incorporation of the TfRscFv-PEG into our lipoplex delivery system increased tumor transgene expression presumably through blockage of the interaction between components of RES and the complex, while not hindering the ligand-receptor interaction. Most significantly, our data indicate that this novel gene delivery system (TsPLP) shows high potential for efficiently and specifically delivering therapeutic genes, and thereby promises to be an effective delivery vehicle for systemic gene therapy of cancer.
Results

In vitro transfection activities
In this study, postcoated TsPLP was prepared essentially according to a strategy described by Blessing et al. 3 Briefly, DNA was mixed with liposomes composed of DOTAP and DOPE (1:1 molar ratio) to form a lipid/DNA complex (lipoplex). Subsequently, heterobifunctional PEG (NHS-PEG-MAL) was added to form a Mal-PEGlipoplex, in which a coupling reaction occurs between the NHS group of bifunctional PEG and the amine residue of DOPE (Figure 1) . Finally, the thiol-functionalized TfRscFv (TfRscFv-SH) was added to form TfRscFv-PEG-lipoplex. The transfection efficiency of TsPLP prepared by this postcoating strategy (TsPLP (post)) was compared with that of TsPLP prepared by a precoating strategy (Figure 1 ), in which a DNA solution was mixed with preformed TfRscFv-PEG liposomes (TsPLP (pre)). In these studies the complexes all included luciferase as a reporter gene. The luciferase activity in prostate cancer cell line DU145 was determined ( Figure  2 ). Dramatically higher transfection activities (over 200-fold) were observed with the TsPLP (post) complex compared to TsPLP (pre). These data demonstrate that the addition of PEG to a lipoplex is extremely effective in increasing transfection efficiency only when PEG is added after the formation of the liposome-DNA complex. This is likely due to the avoidance of PEG interference in complex formation.
To assess whether the gene delivery efficiency of PEGcoated lipoplexes (PLPs) could be improved by conjugation of TfRscFv at the end of the PEG polymer, the transfection activities of unliganded PLP, PLP mixed with, rather than conjugated to, TfRscFv (Ts/PLP) or the conjugated TsPLP (post), all prepared used the postcoating strategy, were compared. TsPLP (post) gave the highest transfection activity, approximately twice that of both PLP and Ts/PLP in DU145 cells (Figure 2 ). Similar results were observed in PANC-1, a pancreatic cancer cell line (data not shown). Thus, conjugation of TfRscFv at the end of PEG increased gene delivery to cells, whereas simple mixing of TfRscFv with PLP had no significant effect on the efficiency of gene delivery. However, it was also observed that PLP (prepared by the postcoating method) yielded a transfection activity about half that observed with the unmodified lipoplex (LP) (Figure 2 ). This may result from inhibition of lipoplex-cell association due to steric hindrance caused by the presence of PEG. Although the addition of the TfRsvFv targeting moiety to the PEG terminus increased the transfection efficiency, this increase still did not bring the transfection level up to that observed with the complex lacking PEG (TsLP), but only made it comparable to the level of unmodified lipoplex (LP). This finding is similar to other reports 5, 7 of decreased transfection efficiency after Tumor targeting by TfRscFv-PEG-lipoplex W Yu et al PEGylation, and increased efficiency after ligand conjugation to the PEG terminus using standard precoating methods. These results suggest that at least in vitro, the inclusion of PEG in the complex decreases gene delivery.
A competition assay was also performed to determine the effect of excess free TfRscFv on transfection activity of TsPLP with either 10-fold (1.5 mg) or 20-fold (3 mg) excess TfRscFv included in the medium during transfection with TsPLP ( Figure 3 ). Excess free TfRscFv inhibited the transfection efficiency of TsPLP in a free TfRscFv dose-dependent manner, indicating that the observed transfection activity of the complex containing PEG is still mediated through the Tf receptor. Taken together, these data demonstrate that the postcoating method, that is, addition of PEG after the formation of the liposome-DNA complex, and the subsequent conjugation of TfRscFv to the distal end of the PEG, avoid both PEG blockage of the targeting molecule and reduce PEG interference with DNA condensation, resulting in a complex that can still transfect cells relatively efficiently. All of the above experiments were repeated at least once with similar results.
Physical characteristics of TsPLP
To assess the influence of PEG or TfRscfv conjugation on the physical characteristics of the complex, the size (by number average) and zeta potential of TsPLP (post) were measured using a Zetasizer 3000HS (Malvern, UK) and compared to those of LP, PLP, TsPLP (pre) and TsLP. Covalent coupling of PEG or TfRscFv-PEG to the lipoplex while slightly increasing the size from 63.276.4 nm to between 85 and 90 nm still results in a complex of o100 nm (Table 1) . This small size is important as it strongly increases the possibility of passive extravasation of TsPLP. 23 In fact, the complex appear to be more compact than the original TsLP, which has a size of 329743 nm. 28 However, inclusion of PEG into the complex did result in a significant decrease in the zeta potential, which is a measure of the overall charge of the molecule. This change most likely represents a masking of the surface charge due to the surrounding PEG cloud. It is interesting that the zeta potentials of both of the 'post-coated' molecules (with and without TfRscFv) have similar values while the 'precoated' molecule is even lower. The significance of these differences will be detailed in the discussion.
TsPLP mediated gene delivery in vitro and in vivo
When comparing the transfection efficiencies of PLP, TsPLP (post) and TsLP (Figures 2) in vitro in DU145 cells, the highest transfection efficiency was observed with TsLP, which was approximately 1.7 times higher than TsPLP and four times higher than the unliganded PLP ( Figure 2 ). Repeat experiments gave similar results. Thus, based upon these in vitro results it would seem there is no benefit to including PEG in the TfRscFv-LipA-DNA complex. However, since the advantage of PEGylation lies in serum stability in vivo, it was more important to compare gene delivery efficiency and tumor specificity in vivo. Employing a DU145 human prostate tumor nude mouse xenograft model, complexes containing the GFP gene were intravenously injected ( Figure 4) . In previous studies, we have routinely administered three i.v. injections of TsPLP complex over 24 h in order to more easily detect transgene expression in the tumor by Western blot analysis. 20 Likewise, in this study we administered three i.v. injections over 24 h of TsPLP (40 mg/injection). For comparison to our original complex without PEG animals also received three injection of TsLP. As controls the unliganded version of the complexes (PLP and LP, respectively) were also i.v injectied into the mice. At 24 h after the last injection the animal were euthanized. Tumor and liver were removed for Western analysis of GFP expression. The relative signal intensity was densitometically analyzed (AlphaImagert, San Leandro, CA, USA). As expected, Figure 4a shows approximately a 10-fold higher level of GFP gene expression in tumor tissue from the animal injected with the TsLP than in tumor tissue from the animal injected with the unliganded LP and a two-to three-fold increase in GFP expression in tumor tissue from the mouse receiving TsPLP versus PLP. More importantly, the level of GFP expression in tumors evident after three i.v. injections with the PEGylated complex (TsPLP) was similar to that observed with TsLP. Both complexes demonstrated tumor preferential targeting as very low levels of GFP expression were evident in the liver. In total, 98% of non-PEGylated liposome are rapidly cleared by the RES. 24 As PEGylation has been shown to offer protection from this nonspecific opsonization, we want to determine if inclusion of PEG in our TfRscFv-LipA-DNA complex using the postcoating method would 
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Tumor targeting by TfRscFv-PEG-lipoplex W Yu et al result in a TsPLP complex that retained this property. If so, the increased availability of the complex should result in increased exogenous gene expression in the tumor. Therefore, to test this hypothesis animals also received a single injection of the various complexes described above. Figure 4b demonstrates that, 24 h after a single i.v. injection, GFP expression was dramatically increased in DU145 tumor xenografts when delivered by TsPLP as compared to TsLP where the signal was barely detectable. Here also, as with three i.v. injections, almost no GFP was expressed in the liver, again demonstrating that the tumor targeting ability of the complex is maintained after inclusion of PEG using this postcoating method. A second experiment has been performed with same result. Similar in vitro and in vivo results were observed in a PANC-1 human pancreatic tumor xenograft model ( Figure 5 ). The in vitro transfection activity of TsLP was significant higher than that of TsPLP (Figure 5a ). However, in vivo (Figure 5b ) approximately a two-fold greater level of exogenous p53 expression was observed in the tumor from the mouse injected once with TsPLP carrying the wtp53 gene. However, in both models (Figure 4b and 5b), expression of GFP or p53 in the liver tissue of these animals was dramatically lower than in the tumor tissue. It should be noted that we have previously found that actin levels differ between human xenograft tumors and normal mouse organs. However, staining with Ponceau S demonstrates approximately equal amounts of protein/lane. Table 2 . While the expression of the control unliganded PLP increases somewhat, it remains at a low background level in the tumor within this time frame. However, the level of expression in the tumor from the TsPLP treated mice increases 43% over time, while that with TsLP shown a 55% decrease to approximately background level between 48 and 96 h. These results demonstrate that inclusion of PEG into the complex results in increased tumor uptake after a single i.v. injection and that this uptake actually increases over time, indirectly supporting the theory that the complex with PEG (TsPLP) is more stable in circulation than that without PEG (TsLP). Thus, TsPLP is a more efficient system for in vivo delivery. After 24 h, the tumors and livers were excised, and the p53 protein band was detected using a monoclonal anti-p53 antibody (Santa Cruz Biotechnology) and enhanced chemiluminescence. The same membrane was subsequently probed with an antiactin antibody to establish equal protein (40 mg) loading per lane. The exogenous Athymic nude mice carrying DU145 subcutaneous xenograft tumors were i.v. injected once with PLP (PEG-coated lipoplex), TsPLP (TfRscFv-PEG-coated lipoplex) and TsLP (our standard TfRscFv lipoplex) carrying the GFP gene (40 mg/0.8 ml per injection). After 48 or 96 h, the tumors were excised, and protein was isolated for Western analysis. The GFP protein band was detected using a monoclonal anti-GFP antibody (BAbCO) and enhanced chemiluminescence. Values represent the relative densitometric intensity of the GFP signal relative to untreated tumor (subtracted as background).
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Discussion
The specific delivery of a therapeutic gene to a tumor is of great importance for successful cancer gene therapy. Toward this aim, in previous studies, 20, 22 a tumor targeting molecule (TfRscFv) was incorporated into a lipoplex, actively targeting the complex to tumor cells following systemic administration. 22 In this study, further modification of the targeting lipoplex was undertaken by incorporating PEG into this system. Coating the lipoplex surface with PEG imposes an hydrophilic steric barrier, which may prevent nonspecific binding of serum proteins, and thus avoid rapid elimination from the bloodstream by phagocytic cells. 25 The resulting increase in blood circulation time of the modified complex could increase the amounts of complex that enter the region of the tumor and subsequently bind to tumor cells.
However, due to this same mechanism, it is possible that PEG may also prevent specific binding of the lipoplex to the target cell, resulting in low intracellular gene delivery. Conjugating the ligand to the PEG terminus could restore the ability of the lipoplex to bind to the targeted cell, thus overcoming this steric hindrance. 12, 26 It has also been proposed that PEG may hinder the electrostatic interaction between negatively charged DNA and positively charged lipids during the forming of the lipoplex, whose structure is critical for efficient gene delivery. 27 Thus, to avoid interference of PEG during the lipoplex formation, a postcoating strategy was utilized instead of a widely used precoating preparation strategy 5, 7 ( Figure 1 ). Using a standard precoating scheme the PEGylated lipoplex (PLP) has been reported to have a gene delivery efficiency which is 100-times 5 to 10 000-times 7 lower than that of the lipoplex without PEGylation (LP). However using our post-coating method, the transfection efficiency of PLP was less than 2 fold lower than that of LP (Figure 2) . At the same time, the TsPLP complex prepared using the precoating method resulted in a transfection efficiency (as assessed by luciferase activity) that was approximately 80-fold lower (Figure 2) . Clearly, this postcoating strategy is preferable to precoating as a means of preparing a ligand-targeted PEGylated lipoplex.
It is interesting to note that comparable in vitro transfection activities of LP and TsPLP (post) were observed. This may be explained by the contradictory effects of adding PEG and TfRscFv to the lipoplex. Incorporation of TfRscFv increases the transfection activity as evidenced with TsLP, whose transfection efficiency is double that of LP. However, incorporation of PEG (PLP) decreased the transfection activity, to about half that of LP. In this case, PEG may be inhibiting the release of DNA from the endosome as was previously reported. 13, 14 These two effects could cancel each other out resulting in a transfection efficiency similar to LP.
While inclusion of PEG (by either pre-or postcoating) had little effect on the size of the complex, there were significant changes in zeta potential. Zeta potential, a measure of the overall change of the complex, is also an indication of the potential stability of the colloidal system. There are two mechanisms that affect this stability, steric repulsion and electrostatic or charge stabilization. Steric repulsion can be influenced by the inclusion of polymers such as PEG in the complex, while electrostatic stabilization results from the distribution of charges in the complex. The presence of PEG while increasing steric repulsion also can mask the overall negative charge of the cationic lipoplex. Thus, the zeta potential values of the complexes with PEG are lower. However, the complexes remain stable and do not precipitate due to the high degree of steric hindrance and repulsion between particles as a result of PEG. The very low zeta value and also transfection efficiency of the TsPLP produced by precoating may be the result of this method of complex formation. Formation of TfRscFv-PEG-liposome prior to addition of the DNA may not, because of the TfRscFv-PEG cloud surrounding the liposome, permit the negatively charged DNA to be fully or correctly encapsulated within the lipoplex, and thus result in a lower overall positive charge and even an incorrect complex structure inhibiting TfRscFv-receptor interaction and consequently, its transfection efficiency.
TfRscFv has been demonstrated to be an excellent tumor targeting ligand in both in vitro and in vivo studies of liposome-mediated gene delivery. 20, 22 As expected, conjugation of TfRscFv at the end of PEG was found to improve gene delivery not only in vitro (Figure 2 ) but also in vivo (Figures 4 and 5b) . It is important to note that simply mixing TfRscFv with PLP (without conjugation) did not improve gene delivery (Figure 2 ). In addition, excess free TfRscFv partially inhibited effective gene delivery by TsPLP in a competitive manner (Figure 3) . Thus, these data demonstrate that conjugation of TfRscFv to the terminus of the PEG polymer is required for effective gene delivery, which occurs through ligandreceptor interaction and receptor-mediated endocytosis.
It has been observed that in vitro studies are not necessarily predictive of in vivo results. 27 However, to date, most targeting sterically stabilized gene delivery vehicles have been studied in vitro. [3] [4] [5] [6] [7] [8] [9] As the ultimate goal of any potential gene therapy is delivery in vivo, a comparison study of TsPLP both in vitro and in vivo was undertaken to elucidate the influence of the PEGylation on gene delivery efficiency. PLP showed the lowest in vitro transfection activity (Figure 2 ), and this is likely due to the PEG molecule preventing association of the lipoplex with the target cell 2, 12 and/or due to PEG inhibition of fusion between lipid and endosomal membrane, which is necessary for the intracellular release of exogenously delivered DNA. 13, 14 As expected, coupling TfRscFv to the end of PEG (TsPLP) increased the transfection activity, possibly due to an increase in targeting, and subsequent association, of the complex to the target cell, consistent with the report of Hofland et al 7 and Fenske et al. 1 However, as noted above, the in vitro transfection activity of TsPLP was still low compared with the lipoplex without PEG (TsLP), while comparable to the the unmodified lipoplex (LP).
As the design of TsPLP was based on the in vivo environment, it was important to evaluate its delivery efficiency in vivo. It is interesting to note that the in vivo results differed significantly with those observed in vitro. In vivo, in both pancreatic and prostate tumor models, TsPLP showed the highest tumor gene expression when compared with LP, PLP or TsLP (Figures 4 and 5b) . Moreover, change in TsPLP-mediated gene expression in the tumor with time was analyzed. As predicted, the tumor GFP expression increased over time, while TsLP mediated levels dropped. This demonstrated that 17, 18, 20, 22 the unliganded complexes, with or without PEG, demonstrated very low in vivo transfection. In addition, both TsPLP and TsLP gave high gene expression in tumor cells but low gene expression in liver cells (Figure 4 and 5b) after both one and three injections demonstrating that including PEG via this postcoating strategy, with the targeting molecule subsequently added at its distal end, allows the complex to maintain its tumor specific nature. Thus, DNA delivery by systemic administration of TsPLP results in selective and efficient delivery of genes to tumor cells.
In conclusion, a sterically stabilized immunolipoplex (TsPLP) was constructed by a PEG postcoating method. The properties conferred by coating with PEG and TfRscFv significantly improves the potency of gene delivery to tumor cells following systemic administration potentially requiring fewer treatments to achieve therapeutic efficacy.
Materials and methods
Materials DOTAP (1,2-dioleoyl-3-trimetylammoniumpropane) and DOPE (dioleoylphosphatidylethanolamine) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Maleimide-PEG-hydroxysuccinimide (MAL-PEG-NHS; MW 3400) was purchased from Shearwater Polymers (HuntsvilleL, AL, USA). Econo-Pac 10DG column was from Bio-Rad (Hercules, CA, USA).
Plasmids
The firefly luciferase (pLuc), green fluorescent protein (pGFP) reporter genes, as well as the p53 gene (1.7 kb complete human wtp53 cDNA), were driven by the cytomegalovirus (CMV) promoter. Plasmids were propagated in Escherichia coli bacterial strain DH 5a and purified using the Mega/Giga plasmid purification kits (QIAGEN, Valencia, CA, USA). The plasmid was quantified spectrophotometrically (A 260 /A 280 values approximately 1.95).
Preparation of TfRscFv directed PEG coated lipoplex (TsPLP): post-and precoated
A schematic representation of the preparation strategy of TsPLP is shown in Figure 1 . Postcoating of TsPLP was performed as described 3 with some modifications. Briefly, 60 ml DNA solution (0.33 mg/ml) was mixed with 140 ml of a 2 mM liposome solution (LipA ¼ DOTAP:DOPE, 1:1 molar ratio) prepared as described. 22 After 15 min at room temperature, 2 ml HEPES (1 M, pH 7.4) and 1.2 ml of a 6 mM MAL-PEG-NHS stock solution in DMSO were added and left for 2 h at room temperature. Subsequently, 6.7 mg TfRscFv-SH, prepared as previously described, 22 was added and left to react overnight at 41C to form TsPLP (post).
Precoated TsPLP was prepared as follows: 2 ml HEPES (1 M, pH 7.4) and 1.2 ml of a 6 mM NHS-PEG-MAL stock solution in DMSO was added to 140 ml liposome (2 mM). After 2 h at room temperature, 6.7 mg of TfRscFv-SH was added and left to react overnight at 41C. The resulting TfRscFv-PEG-LipA was mixed with 60 ml DNA (0.33 mg/ ml) solution to form TsPLP (Pre).
The sizes (number average), zeta potential and polydispersity index (PDI) of LP, PLP, TsPLP and TsPLP (pre) were measured using a Zetasizer 3000HS (Malvern, UK). The measurement was performed under the conditions of 251C, 901 scattering angle and analysis model CONTIN. Polydispersity index is representative of homogeneity.
Preparation of TsLP and PLP (post)
The TsLP was prepared as described. 18 Briefly, 140 ml LipA was added to 6.7 mg TfRscFv solution and left to stand 15 min at room temperature. Subsequently, 60 ml DNA (0.33 mg/ml) was added and left to stand 15 min at room temperature to form TsLP. PLP (post) was prepared as described for TsPLP above, but without the addition of TfRscFv-SH.
Cell culture and transfection
Cells from the PANC-1 human pancreatic cell line (ATCC CRL-1469) were incubated in Iscove's Minimum Essential Medium supplemented with Phenol Red (IM). DU145 human prostate cancer cells (ATCC HTB-81) were maintained in Minimum Essential Medium supplemented with Earle's salts (MEM). Cell media were supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine plus 50 mg/ml each of penicillin, streptomycin and neomycin.
In total, 5 Â 10 4 PANC-1 or DU145 cells were seeded per well in a 24-well plate. After 24 h, the medium containing 10% FBS was replaced with serum-free medium and the cells transfected with complexes carrying the luciferase gene (0.5 mg pLuc per well) as previously described. 22 After 4 h incubation, serum was added to a final concentration of 10%. At 24 h posttransfection, luciferase activity was determined using a Luciferase Assay System (Promega, Madison, WI, USA) and protein concentration measured using BCAt protein assay kit (Pierce, Rockford, IL, USA), according to the manufacturer's protocols. The enzyme activity, reported as relative light units (RLU) per mg total protein, is indicative of the transfection efficiency.
For the TfRscFv competition assay, 10 or 20 times excess free TfRscFv (1.5 or 3 mg per well respectively) were added to the medium before cells were transfected with TsPLP.
Gene delivery in vivo
Human xenograft mouse tumor models were used in this study. For the prostate cancer model, 6 Â 10 6 DU145 cells were suspended in MatriGel collagen basement membrane (Collaborative Biomedical Products, Bedford, MA, USA) and injected subcutaneously into the lower back above the tail of 4-6-week-old female athymic nude mice. Tumors were allowed to develop to a size of approximately 100 mm The lipoplexes (in 5% dextrose) carrying p53 or pGFP (40 mg DNA per injection), prepared as described above, were intravenously injected either one or three times within 24 h. At 24, 48 or 96 h after the last, or the single injection, animals were euthanized, the tumor and liver were excised, and protein was isolated for Western analysis. 22 Protein isolated from the tumor and liver of an untreated animal was included as a control. A total of 80 mg protein per sample was separated by 10% SDS polyacrylamide gel electrophoresis and analyzed by Western Blot. The GFP protein band was detected using a monoclonal anti-GFP antibody (BabCo, Richmond, CA, USA) and the p53 protein band was detected using a monoclonal anti-p53 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Both were visualized by enhanced chemiluminescence (ECL) (Amersham, Arlington Heights, IL, USA). The same membrane was subsequently treated with an antiactin antibody to establish equal protein loading per lane.
Densitometric analysis was performed on the Western blot using an AlphaImagert (San Leandro, CA, USA).
